Lipid metabolism and inflammatory cytokine pathway targets

Lipid metabolism and inflammatory cytokine pathway targets represent a diverse group of proteins that mediate the crosstalk between metabolic health and the immune system. This category primarily includes nuclear receptors such as Peroxisome Proliferator-Activated Receptors (PPAR-alpha, -gamma, -delta) and Liver X Receptors (LXR-alpha, -beta), which function as ligand-activated transcription factors [PMID: 21115611]. These receptors regulate the expression of genes involved in fatty acid oxidation, cholesterol transport, and glucose uptake, while simultaneously exerting anti-inflammatory effects by inhibiting the NF-kappaB signaling pathway [PMID: 17330091]. Chronic activation of these pathways is linked to meta-inflammation, a low-grade systemic inflammatory state driven by nutrient excess and metabolic dysfunction [PMID: 17171074]. Pharmacological modulation of these targets, such as through PPAR agonists (e.g., thiazolidinediones) or cytokine inhibitors (e.g., anti-TNF agents), aims to resolve metabolic disorders like type 2 diabetes and atherosclerosis by improving insulin sensitivity and reducing vascular inflammation [PMID: 25648237]. These targets are also central to the pathology of non-alcoholic steatohepatitis (NASH), where lipid accumulation triggers cytokine-mediated liver injury [PMID: 27641101]. Therapeutic development in this area is often challenged by side effects such as fluid retention, weight gain, or off-target metabolic disturbances [PMID: 15102986]. Overall, these targets provide a critical link for treating complex diseases where lipid metabolic failure and chronic inflammation are inextricably intertwined.

Other names

Metabolic-inflammatory axisImmunometabolism targetsMeta-inflammation pathwaysNutrient-sensing inflammatory pathways

Modulation of nuclear receptors to regulate gene expression of metabolic enzymes and inflammatory cytokines, or direct inhibition of pro-inflammatory cytokine signaling to resolve meta-inflammation.